Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX LM W DEXTROSE 3 5 IN PLASTIC CONTAINER versus DIALYTE LM DEXTROSE 1 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX LM W DEXTROSE 3 5 IN PLASTIC CONTAINER versus DIALYTE LM DEXTROSE 1 5 IN PLASTIC CONTAINER.
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER vs DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DELFLEX-LM W/ DEXTROSE 3.5% is a peritoneal dialysis solution. Its mechanism of action involves osmotic ultrafiltration across the peritoneal membrane, facilitated by high dextrose concentration, to remove excess fluid and waste products (e.g., urea, creatinine) from the blood in patients with end-stage renal disease.
Peritoneal dialysis solution with dextrose as osmotic agent; dextrose creates osmotic gradient across peritoneal membrane to remove excess fluid and uremic toxins.
Intraperitoneal: 1.5% to 4.25% dextrose solution; 2 to 2.5 L per exchange, typically 4 exchanges per 24 hours; dwell time 4 to 6 hours.
Intraperitoneal administration via automated peritoneal dialysis (APD) or continuous ambulatory peritoneal dialysis (CAPD); typical adult dose is 2-3 liters per exchange, 4-5 exchanges per day (CAPD) or 8-12 liters total volume per night (APD).
None Documented
None Documented
Not applicable for dextrose; for lactate/bicarbonate buffer components, half-life is approximately 2-4 hours in peritoneal cavity with systemic absorption minimal. Clinical context: continuous dialysis maintains steady-state.
Not applicable: Dextrose absorbed from peritoneal dialysate has a half-life similar to IV glucose (approx. 1-2 hours), but as a dialysis solution, the concept of terminal elimination half-life is not defined for the non-absorbed components. Clinical context: continuous intraperitoneal administration.
Peritoneal dialysis: Removal of waste products (urea, creatinine) via peritoneal membrane; approximately 60-80% of urea is removed during a 4-6 hour dwell. Biliary/fecal: minimal (<5%). Renal: negligible as drug is primarily used in renal failure.
Peritoneal dialysis fluid: DIALYTE components (electrolytes, dextrose) are not systemically absorbed in clinically significant amounts; dextrose is partially absorbed across the peritoneum and metabolized. Renal and biliary excretion are not relevant as this is a topical intraperitoneal solution. Elimination of absorbed dextrose follows glucose metabolism (oxidation, storage).
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution